智翔金泰跌2% 连亏4年3季2023年上市募34.7亿

Core Viewpoint - Zhixiang Jintai (688443.SH) is currently experiencing a decline in stock price, with a market value of 11.294 billion yuan and is in a state of breaking issue since its IPO in June 2023 [1] Group 1: Company Financials - Zhixiang Jintai has reported losses for four consecutive years and three quarters, with net profits attributable to shareholders of -322 million yuan in 2021, -576 million yuan in 2022, -801 million yuan in 2023, and -797 million yuan in 2024 [2] - The company’s net profit excluding non-recurring gains and losses for the same years were -334 million yuan, -645 million yuan, -813 million yuan, and -804 million yuan respectively [2] - In the first three quarters of 2025, Zhixiang Jintai achieved operating revenue of 208 million yuan, a significant increase of 1,562.05% year-on-year, but still reported a net loss of -333 million yuan attributable to shareholders [2] Group 2: IPO and Fundraising - Zhixiang Jintai was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 20, 2023, with an initial public offering of 91.68 million shares at a price of 37.88 yuan per share [1] - The total amount raised from the IPO was 3.472 billion yuan, with a net amount of 3.291 billion yuan after deducting issuance costs, which was 688.6 million yuan less than the originally planned fundraising amount of 3.98 billion yuan [1] - The total issuance costs amounted to 181.44 million yuan, including underwriting fees of 164.96 million yuan [1]

Chongqing Genrix Biopharmaceutical -智翔金泰跌2% 连亏4年3季2023年上市募34.7亿 - Reportify